Eurosurveillance最新文献

BackgroundHealth inequalities exist globally, but limited data exist on this topic for bacteraemia.AimIn this study we investigated health inequalities surrounding bacteraemia in England, to identify high-risk population groups and areas of intervention.MethodsWe retrospectively analysed English surveillance data between 2018 and 2022 for Escherichia coli, Klebsiella species, Pseudomonas aeruginosa, and both meticillin-sensitive and resistant Staphylococcus aureus (MSSA, MRSA) bacteraemia. Crude incidence rates stratified by index of multiple deprivation and ethnic groups were calculated; age-adjusted rate ratios were estimated using negative binomial regression models.ResultsWe identified 342,787 bacteraemia cases. Across all pathogens, as the level of deprivation rose, so did the age-adjusted bacteraemia incidence rate ratio. Compared with residents of the 20% least deprived areas of England, residents of the 20% most deprived areas had a 2.68-fold increased bacteraemia rate for MRSA (95% CI: 2.29-3.13) and 1.95-fold for E. coli (95% CI: 1.84-2.05), and 15% higher odds of dying within 30 days of any bacteraemia (95% CI: 1.13-1.19). After age adjustment, the incidence of all bacteraemia was higher in the Asian and Black groups compared with the White group: for MRSA, 79% higher in the Asian (95% CI: 1.51-2.10) and 59% higher in the Black (95% CI: 1.29-1.95) groups. The exception was MSSA, whose incidence was highest in the White group.ConclusionDisproportionately higher age-adjusted incidence of bacteraemia occurred in deprived areas and ethnic minorities. These disparities are likely multifactorial, possibly including socioeconomic, cultural, and systemic risk factors and different burden of comorbidities. Better understanding these factors can enable targeted interventions.

BackgroundLaboratory surveillance detected an unprecedented increase in Cryptosporidium spp. (predominantly Cryptosporidium hominis) in England and Wales in August 2023. Cases are not routinely followed up in all of England and Wales, and initial investigations identified no common exposures.AimTo perform a retrospective case-case study investigation of the increase in Cryptosporidium spp. in England and Wales.MethodsWe conducted an unmatched case-case study with 203 cases of laboratory-confirmed C. hominis and 614 comparator cases of laboratory-confirmed Campylobacter spp. reported between 14 August and 30 September 2023. We fitted a multilevel logistic regression model, with random intercepts for geographical region, to estimate adjusted odds ratios (aOR) for exposures. We present the final model as aOR and 95% confidence intervals (CI).ResultsMultivariable analysis identified associations with swimming pool use (aOR: 5.3, 95% CI: 2.3-9.3), travel to Spain (aOR: 6.5, 95% CI: 3.5-12.3) and young age, with children 0-4 years having the strongest association of being a case (aOR: 3.6, 95% CI: 1.5-8.6). We also identified associations with swimming in a river, and travel to France or Türkiye, but there was low frequency of exposure among cases and comparator cases.ConclusionsFollowing the largest recorded increase of Cryptosporidium spp. and in particular C. hominis cases in England and Wales, we identified several exposures, suggesting that causation was likely to be multifactorial. We recommend development of a standardised questionnaire to enable rapid investigation of future case increases, which will improve existing surveillance and inform public health actions.

BackgroundStaphylococcus haemolyticus (SH) is an opportunistic pathogen associated with nosocomial infections, particularly bacteraemia in neonates. Epidemiological trends and genetic diversity of these infections worldwide are largely unknown.AimTo investigate an increase in SH vascular catheter-related bacteraemia in neonates and describe the molecular epidemiology in France between 2019 and 2023.MethodsWe analysed clinical and microbiological surveillance data from the French national surveillance network for central catheter-related (venous and umbilical) infections between 2019 and 2023. We also performed genomic and phylogenetic analyses of 496 strains isolated both inside (n = 383 from neonates, staff and environmental samples) and outside (n = 113 from adults) the neonatal intensive care unit (NICU) settings.ResultsThe proportion of SH among the 474 reported cases of nosocomial bacteraemia increased from about 20% to 30% over 5 years, mainly affecting very low birth weight preterm neonates (≤ 1,500 g). The ST29 sequence type (ST) not prevalent in previous studies was predominant, accounting for 74% of NICU strains. ST29 was characterised by phenotypic multidrug resistance to at least six classes of antibiotics (oxacillin, quinolones, gentamicin, cotrimoxazole, clindamycin and rifampicin), which distinguished it with good sensitivity and specificity from other prevalent multidrug-resistant STs identified (ST1 and ST25). ST29 strains more frequently harboured the drfG, vga-LC and mupA genes and a triple point mutation (D471E, I527M and S532N) in the rpoB gene.ConclusionsThe present study highlights the success of a highly resistant ST29 lineage in French NICUs mainly affecting very low birth weight premature neonates.

BackgroundAmbient temperature may affect respiratory health, while the temperature sensitivity of respiratory infections may be pathogen-dependent.AimsWe sought to explore pathogen-specific associations between ambient temperature and respiratory infections.MethodsWe searched nine databases for a random-effects meta-analysis to pool the relative risk (RR) of respiratory infection by pathogen per 1° C temperature rise, compared to populations unexposed to the same temperature. We conducted pathogen-specific analyses, sensitivity analyses, subgroup analyses and meta-regression.ResultsA total of 137 studies were eligible for meta-analysis. The pooled and single-study estimates revealed that the incidence of respiratory syncytial virus (RR = 0.14; 95% confidence interval (CI): 0.09-0.23), influenza virus (IV) (RR = 0.40; 95% CI: 0.27-0.61), human metapneumovirus (RR = 0.48; 95% CI: 0.32-0.73), human coronavirus (HCoV) (RR = 0.21; 95% CI: 0.07-0.61) and SARS-CoV-2 (RR = 0.52; 95% CI: 0.35-0.78) decreased per 1° C temperature rise, while that of human parainfluenza virus (HPIV) (RR = 2.35; 95% CI: 1.46-3.77), human bocavirus (HBoV) (RR = 1.86; 95% CI: 1.04-3.32) and MERS-CoV (RR = 1.05; 95% CI: 1.04-1.07) increased. The risk of infection was lower for IVA, IVB, HCoV-229E and HCoV-OC43, while HPIV-3, and HBoV-1 were at increased risk. The risk of Streptococcus pyogenes pharyngitis (RR = 0.46; 95% CI: 0.30-0.69) decreased per 1° C temperature rise, while Pseudomonas aeruginosa (RR = 1.04; 95% CI: 1.03-1.05) and Legionella pneumophila infections (RR = 2.69; 95% CI: 1.11-6.53) increased.ConclusionsTemperature sensitivity of respiratory infections can vary with the specific pathogen type and subtype that causes the infection. As the climatic conditions will become warmer, public health policy makers should act to develop pathogen adaptation strategies.

We report two importations of monkeypox virus clade Ib infection to the United Kingdom in 2024. The first was a traveller returning from Tanzania, Rwanda and Uganda, the second from Uganda. Both presented with fever and typical skin lesions; 147 contacts were followed up, 19 vaccinated with MVA-BN. Three household contacts of the first individual, including two children, became infected. These are the first reported autochthonous transmissions of clade Ib in Europe, and first paediatric cases outside the African continent.

In October 2024, an infection of European bat lyssavirus type 1 was confirmed in a domestic cat in the Netherlands. Several weeks before, the owners had found a dead bat considered to be caught by the cat. Nine persons exposed to the cat received post-exposure prophylaxis and four domestic animals from the same household were quarantined. This report stresses the need for vigilance for rabies in domestic animals in countries where lyssavirus infections in bats are endemic.

BackgroundMonoclonal antibodies (mAbs) and antiviral drugs have emerged as additional tools for treatment of COVID-19.AimWe aimed to review data on susceptibility of 14 SARS-CoV-2 variants to mAbs and antiviral drugs authorised in the European Union/European Economic Area (EU/EEA) countries.MethodsWe constructed a literature review compiling 298 publications from four databases: PubMed, Science Direct, LitCovid and BioRxiv/MedRxiv preprint servers. We included publications on nirmatrelvir and ritonavir, remdesivir and tixagevimab and cilgavimab, regdanvimab, casirivimab and imdevimab, and sotrovimab approved by the European Medicines Agency (EMA) by 1 October 2024.ResultsThe mutations identified in the open reading frame (ORF)1ab, specifically nsp5:H172Y, nsp5:H172Y and Q189E, nsp5:L50F and E166V and nsp5:L50F, E166A and L167V, led to a decrease in susceptibility to nirmatrelvir and ritonavir, ranging from moderate (25-99) to high reductions (> 100). Casirivimab and imdevimab exhibited highly reduced neutralisation capacity across all Omicron sub-lineages. Sub-lineages BA.1, BA.2 and BA.5 had decreased susceptibility to regdanvimab, while sotrovimab showed decreased efficacy for BA.2, BA.4, BQ.1.1 and BA.2.86. Tixagevimab and cilgavimab exhibited highly reduced neutralisation activity against BQ.1, BQ.1.1, XBB, XBB.1.5 and BA.2.86 sub-lineages.ConclusionsThe emergence of new variants, some with altered antigenic characteristics, may lead to resistance against mAbs and/or antiviral drugs and evasion of immunity induced naturally or by vaccination. This summary of mutations, combination of mutations and SARS-CoV-2 variants linked to reduced susceptibility to mAbs and antiviral drugs, should aid the selection of appropriate treatment strategies and/or phasing out therapies that have lost their effectiveness.